Free Trial

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$2.37 -0.11 (-4.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.34 -0.03 (-1.43%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Key Stats

Today's Range
$2.35
$2.53
50-Day Range
$0.61
$3.04
52-Week Range
$0.51
$3.22
Volume
969,965 shs
Average Volume
1.24 million shs
Market Capitalization
$132.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

SPRO MarketRank™: 

Spero Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 229th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spero Therapeutics has received no research coverage in the past 90 days.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Spero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.22% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Spero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.22% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Spero Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • Search Interest

    Only 2 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $1.03 on January 1st, 2025. Since then, SPRO stock has increased by 130.1% and is now trading at $2.37.

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.30. The business earned $5.87 million during the quarter, compared to the consensus estimate of $11 million. Spero Therapeutics had a negative net margin of 156.48% and a negative trailing twelve-month return on equity of 123.50%.

Spero Therapeutics (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional investors of Spero Therapeutics include Capital Asset Advisory Services LLC (0.06%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends
.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/13/2025
Today
7/18/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRO
CIK
1701108
Fax
N/A
Employees
150
Year Founded
2013

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+106.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.57 million
Net Margins
-156.48%
Pretax Margin
-156.48%
Return on Equity
-123.50%
Return on Assets
-58.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.56
Quick Ratio
2.56

Sales & Book Value

Annual Sales
$47.98 million
Price / Sales
2.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.85 per share
Price / Book
2.85

Miscellaneous

Outstanding Shares
55,910,000
Free Float
52,836,000
Market Cap
$135.58 million
Optionable
Optionable
Beta
1.33

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners